Pharmacological Evaluation of Newly Synthesised Cannabinoid Derivatives on H9c2 Cells

A tétel rövid nézete
dc.contributor.advisorFesus, Adina
dc.contributor.advisordeptGyógyszerésztudományi Kar::Gyógyszerhatástani Tanszék
dc.contributor.authorJaved, Muhammad Bilal
dc.contributor.departmentDE--Gyógyszerésztudományi Kar
dc.date.accessioned2024-04-18T13:06:55Z
dc.date.available2024-04-18T13:06:55Z
dc.date.created2024-02-03
dc.description.abstractILKA molecules are nationally developed cannabinoid and bixin containing derivatives with expected antioxidant effects. The aim of our study was to investigate whether pretreatment with ILKA 675 and ILKA 676 molecules has a protective effect against hypoxia-reoxygenation (H/R) induced acute injury on cardiac myocytes. In our series of experiments the H9c2 rat cardiomyoblast cells were treated for 24 hours and the IC50 values of the molecules were determined. After that, we investigated the cell viability using MTT assay. The concentration of 30 µM proved to be the most effective. Subsequently, this concentration was used to pretreat cardiomyocytes followed by four/three hours of H/R. The LDH assay was carried out to give information regarding the cytotoxicity of the molecules. Furthermore, antioxidant assays such as TEAC (Trolox Equivalent Antioxidant Capacity), FRAP (Ferric Reducing Antioxidant Power) and ORAC (Oxygen Radical Absorbance Capacity) were carried out to evaluate the antioxidant properties of the molecules. Our findings demonstrate that the pretreatment with the newly synthesised molecules significantly improved the cardiomyocytes viability after H/R. ILKA 675 was the least cytotoxic under hypoxic conditions. Furthermore, ILKA 675 showed the highest antioxidant activity according to the results obtained from the antioxidant assays. Overall, ILKA 675 and ILKA 676 may have a beneficial effect in the prevention of H/R induced cytotoxicity through the reduction of oxidative stress.
dc.description.coursegyógyszerész
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent30
dc.identifier.urihttps://hdl.handle.net/2437/368995
dc.language.isoen
dc.rights.accessHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectantioxidant
dc.subjectcannabinoid
dc.subjectcannabidiol
dc.subjectcannabigerol
dc.subjectbixin
dc.subjectstimulated hypoxia/reperfusion
dc.subject.dspaceMedicine::Pharmacology
dc.titlePharmacological Evaluation of Newly Synthesised Cannabinoid Derivatives on H9c2 Cells
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 2 (Összesen 2)
Nincs kép
Név:
Javed Muhammad Bilal Research Final version.pdf
Méret:
1.72 MB
Formátum:
Adobe Portable Document Format
Leírás:
Javed Muhammad Bilal TDK - Pharmacological Evaluation of Newly Synthesised Cannabinoid Derivatives on H9c2 Cells.
Megjelenítés
Nincs kép
Név:
Declaration plagium signed.pdf
Méret:
121.75 KB
Formátum:
Adobe Portable Document Format
Leírás:
Signed declaration.
Megjelenítés
Engedélyek köteg
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
license.txt
Méret:
1.94 KB
Formátum:
Item-specific license agreed upon to submission
Leírás:
Letöltés
Gyűjtemények
Theses (Faculty of Pharmacy)